Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in trading and manufacturing of Pharmaceutical drugs and provides services and key solutions in Information Technology.
- Market Cap ₹ 10.9 Cr.
- Current Price ₹ 10.8
- High / Low ₹ 18.9 / 9.61
- Stock P/E
- Book Value ₹ 22.6
- Dividend Yield 0.00 %
- ROCE -28.4 %
- ROE -22.7 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.47 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.18% over past five years.
- Promoter holding is low: 16.4%
- Company has a low return on equity of -4.13% over last 3 years.
- Promoter holding has decreased over last 3 years: -17.8%
- Working capital days have increased from 117 days to 252 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 18.09 | |
| 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 29.84 | 29.95 | |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -7.23 | -11.86 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -31.98% | -65.56% |
| 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | 1.32 | 1.17 | |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.49 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -11.18 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | |
| 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -9.46 | |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -9.37 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -30% |
| TTM: | -47% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -4400% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 5% |
| 5 Years: | -14% |
| 3 Years: | -38% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 10% |
| 3 Years: | -4% |
| Last Year: | -23% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 |
| 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 | |
| 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 | |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 |
| 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.80 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 5.49 | 0.00 |
| 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 25.23 | 22.96 | |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| -0.10 | 0.23 | -15.18 | 1.83 | 8.26 | -1.56 | 4.85 | -9.82 | |
| 0.00 | -0.02 | -0.01 | -0.31 | -1.13 | -4.28 | -1.79 | 3.07 | |
| 0.09 | 0.07 | 16.36 | 3.99 | 1.30 | -2.15 | -1.17 | 0.24 | |
| Net Cash Flow | -0.01 | 0.28 | 1.17 | 5.51 | 8.43 | -7.99 | 1.90 | -6.51 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Inventory Days | 91.25 | 19.70 | 0.00 | |||||
| Days Payable | 511.00 | 192.66 | ||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 251.51 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -28.43% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Friday, 05Th September, 2025.
9h - Appointed secretarial/internal auditors, re‑appointed independent director; AGM set for 30.09.2025, scrutinizer appointed.
-
Announcement under Regulation 30 (LODR)-Change in Management
9h - Board appointed auditors, re‑appointed Independent Director; AGM set for 30.09.2025; e-voting scrutinizer appointed.
-
Announcement under Regulation 30 (LODR)-Change in Management
14 Aug - Q1 FY26 results approved; director resigned; Bahrain office closed; SEBI penalty with no material impact.
- Unaudited Financial Results For The Quarter Ended 30.06.2025 14 Aug
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 14.08.2025
14 Aug - Q1 FY25 unaudited results approved; director resigned; Bahrain office closure; SEBI penalty with no material impact.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Services Offered:[1][2]
a) Pharmaceuticals: Manufacturing & Marketing of Branded Formulations and Custom Manufacturing for companies. Company also caters to various formulators, manufacturers and Research and Development agencies for their Bulk needs and sources and supplies various drugs and allied products & services to companies upon request.
b) Information Technology: Company has taken over Decipher Software Solutions LLC in USA which is an Information Technology services firm, specializing in ERP Implementation, Mobile & Cloud solutions, Product Development, Offshore Services, Technology Integration and Systems Consulting, Software Development Consulting and Management of IT projects.